Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS

Objectives: To assess differences in the use of analgesics, sedatives and neuromuscular-blocking agents (NMBA) in patients with acute respiratory distress syndrome (ARDS) due to COVID-19 or other conditions. Methods: Retrospective observational cohort study, single-center tertiary Intensive Care Uni...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amédée Ego, Lorenzo Peluso, Julie Gorham, Alberto Diosdado, Giovanni Restuccia, Jacques Creteur, Fabio Silvio Taccone
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	COVID-19 acute respiratory distress syndrome sedation neuromuscular-blocking agents Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/6d9ecbe9d3c04747a2cd7620d67f3de4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6d9ecbe9d3c04747a2cd7620d67f3de4
record_format	dspace
spelling	oai:doaj.org-article:6d9ecbe9d3c04747a2cd7620d67f3de42021-11-25T18:25:39ZUse of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS10.3390/microorganisms91123932076-2607https://doaj.org/article/6d9ecbe9d3c04747a2cd7620d67f3de42021-11-01T00:00:00Zhttps://www.mdpi.com/2076-2607/9/11/2393https://doaj.org/toc/2076-2607Objectives: To assess differences in the use of analgesics, sedatives and neuromuscular-blocking agents (NMBA) in patients with acute respiratory distress syndrome (ARDS) due to COVID-19 or other conditions. Methods: Retrospective observational cohort study, single-center tertiary Intensive Care Unit. COVID-19 patients with ARDS (March–May 2020) and non-COVID ARDS patients (2017–2020) on mechanical ventilation and receiving sedation for at least 48 h. Results: A total of 39 patients met the inclusion criteria in each group, with similar demographics at baseline. COVID-19 patients had a longer duration of MV (median 22 (IQRs 16–29) vs. 9 (6–18) days; <i>p</i> < 0.01), of sedatives administration (18 (11–22) vs. 5 (4–9) days; <i>p</i> < 0.01) and NMBA therapy (12 (9–16) vs. 3 (2–7) days; <i>p</i> < 0.01). During the first 7 days of sedation, compared to non-COVID patients, COVID patients received more frequently a combination of multiple sedative drugs (76.9% vs. 28.2%; <i>p</i> < 0.01) and a higher NMBA regimen (cisatracurium: 3.0 (2.1–3.7) vs. 1.3 (0.9–1.9) mg/kg/day; <i>p</i> < 0.01). Conclusions: The duration and consumption of sedatives and NMBA was significantly increased in patients with COVID-19 related ARDS than in non-COVID ARDS. Different sedation strategies and protocols might be needed in COVID-19 patients with ARDS, with potential implications on long-term complications and drugs availability.Amédée EgoLorenzo PelusoJulie GorhamAlberto DiosdadoGiovanni RestucciaJacques CreteurFabio Silvio TacconeMDPI AGarticleCOVID-19acute respiratory distress syndromesedationneuromuscular-blocking agentsBiology (General)QH301-705.5ENMicroorganisms, Vol 9, Iss 2393, p 2393 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 acute respiratory distress syndrome sedation neuromuscular-blocking agents Biology (General) QH301-705.5
spellingShingle	COVID-19 acute respiratory distress syndrome sedation neuromuscular-blocking agents Biology (General) QH301-705.5 Amédée Ego Lorenzo Peluso Julie Gorham Alberto Diosdado Giovanni Restuccia Jacques Creteur Fabio Silvio Taccone Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS
description	Objectives: To assess differences in the use of analgesics, sedatives and neuromuscular-blocking agents (NMBA) in patients with acute respiratory distress syndrome (ARDS) due to COVID-19 or other conditions. Methods: Retrospective observational cohort study, single-center tertiary Intensive Care Unit. COVID-19 patients with ARDS (March–May 2020) and non-COVID ARDS patients (2017–2020) on mechanical ventilation and receiving sedation for at least 48 h. Results: A total of 39 patients met the inclusion criteria in each group, with similar demographics at baseline. COVID-19 patients had a longer duration of MV (median 22 (IQRs 16–29) vs. 9 (6–18) days; <i>p</i> < 0.01), of sedatives administration (18 (11–22) vs. 5 (4–9) days; <i>p</i> < 0.01) and NMBA therapy (12 (9–16) vs. 3 (2–7) days; <i>p</i> < 0.01). During the first 7 days of sedation, compared to non-COVID patients, COVID patients received more frequently a combination of multiple sedative drugs (76.9% vs. 28.2%; <i>p</i> < 0.01) and a higher NMBA regimen (cisatracurium: 3.0 (2.1–3.7) vs. 1.3 (0.9–1.9) mg/kg/day; <i>p</i> < 0.01). Conclusions: The duration and consumption of sedatives and NMBA was significantly increased in patients with COVID-19 related ARDS than in non-COVID ARDS. Different sedation strategies and protocols might be needed in COVID-19 patients with ARDS, with potential implications on long-term complications and drugs availability.
format	article
author	Amédée Ego Lorenzo Peluso Julie Gorham Alberto Diosdado Giovanni Restuccia Jacques Creteur Fabio Silvio Taccone
author_facet	Amédée Ego Lorenzo Peluso Julie Gorham Alberto Diosdado Giovanni Restuccia Jacques Creteur Fabio Silvio Taccone
author_sort	Amédée Ego
title	Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS
title_short	Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS
title_full	Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS
title_fullStr	Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS
title_full_unstemmed	Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS
title_sort	use of sedatives and neuromuscular-blocking agents in mechanically ventilated patients with covid-19 ards
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/6d9ecbe9d3c04747a2cd7620d67f3de4
work_keys_str_mv	AT amedeeego useofsedativesandneuromuscularblockingagentsinmechanicallyventilatedpatientswithcovid19ards AT lorenzopeluso useofsedativesandneuromuscularblockingagentsinmechanicallyventilatedpatientswithcovid19ards AT juliegorham useofsedativesandneuromuscularblockingagentsinmechanicallyventilatedpatientswithcovid19ards AT albertodiosdado useofsedativesandneuromuscularblockingagentsinmechanicallyventilatedpatientswithcovid19ards AT giovannirestuccia useofsedativesandneuromuscularblockingagentsinmechanicallyventilatedpatientswithcovid19ards AT jacquescreteur useofsedativesandneuromuscularblockingagentsinmechanicallyventilatedpatientswithcovid19ards AT fabiosilviotaccone useofsedativesandneuromuscularblockingagentsinmechanicallyventilatedpatientswithcovid19ards
_version_	1718411203349315584

Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS

Ejemplares similares